Condition: Heart Failure · Sponsor: University Hospital, Montpellier
Management of patients with heart Failure remains a major health concern because of the high rate of rehospitalization, mortality and induced-cost. Biomarkers could help to guide the management of patients with heart failure (HF). Soluble suppression of tumorigenicity 2 (sST2) appears as a promising biomarker. As a working hypothesis, we postulate that sST2 values monitoring could be an helpful guide for medical management in an attempt to reduce hospital readmission.
This description comes directly from the study's public registry record.
Jean-Paul CRISTOL, MD, PhD · (0)4 67 33 83 14 · jp-cristol@chu-montpellier.fr
Anne-Marie GORCE DUPUY · (0)4 67 33 79 61 · am-dupuy@chu-montpellier.fr
Always discuss trial participation with your own doctor first.
| Lapeyronie Hospital | Montpellier, Occitanie, France | Active Not Recruiting |
| CHU Angers | Angers, France | Recruiting |
| CHU Besançon | Besançon, France | Recruiting |
| CH Béziers | Béziers, France | Recruiting |
| CHU Caen | Caen, France | Recruiting |
| CHU Grenoble | Grenoble, France | Recruiting |
| Arnaud de Villeneuve Hospital | Montpellier, France | Recruiting |
| CHU Nimes | Nîmes, France | Recruiting |
| APHP Pompidou | Paris, France | Not Yet Recruiting |
| CHU Rennes | Rennes, France | Not Yet Recruiting |
| CHU Toulouse | Toulouse, France | Recruiting |
| CHU Vannes | Vannes, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04554277